The FDA granted accelerated approval to the antibody–drug conjugate trastuzumab deruxtecan for the treatment of patients with non–small cell lung cancer bearing oncogenic HER2 mutations who have experienced disease progression following systemic platinum-based therapy.

中文翻译：

---

FDA 批准 T-DXd 治疗 HER2 突变非小细胞肺癌

FDA 加速批准了抗体药物偶联物 trastuzumab deruxtecan，用于治疗携带致癌 HER2 突变的非小细胞肺癌患者，这些患者在全身铂类治疗后出现疾病进展。